Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 10, 2019
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
[ Fri, May 10th 2019
] - WOPRAI
Thu, May 9, 2019
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
Brian Abrahams Maintained (SRPT) at Buy with Decreased Target to $188 on, May 9th, 2019
Brian Abrahams of RBC Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $191 to $188 on, May 9th, 2019.
Brian has made no other calls on SRPT in the last 4 months.
There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Brian's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Brian
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $169 on, Monday, March 4th, 2019
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $201 on, Friday, March 1st, 2019
- Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $231 on, Thursday, February 28th, 2019
- Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $230 on, Thursday, February 28th, 2019
